drugset / Trial / NCT00855413

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

NCT00855413 ↗

NaSingle-groupOpen-labelTreatment

Summary

Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine Participants: 20 participants, age 18 and older, HIV infected, antiretroviral naïve patients Procedures (methods): ARV treatment with Darunavir/ritonavir and Etravirine, Optional studies: Genital secretion samples, Cerebrospinal fluid samples, Leukapheresis, Endoscopy/colonoscopy

Timeline

Start
2009-03
Primary completion
2013-11
Completion
2013-11

Outcome

Outcome not reported

Stopped (Enrollment): “Study halted by sponsor due to slow enrollment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 800 mg Oral
Subject Etravirine Small molecule 200 mg Oral
Subject Etravirine Small molecule 400 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral